$7.03
-0.07 (-0.99%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where IOVA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
15 interventional · 1 expanded access · 3 with posted results
Held by 13 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, MILLENNIUM MANAGEMENT LLC, JANE STREET GROUP, LLC, AQR CAPITAL MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, +8 more) · FINRA short interest 6.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of IOV-5001 in Adults With Advanced Solid TumorsNCT07743723Phase 1: Safety AssessmentNon-randomized · Open-label · Treatment | Phase 1/2 | Not yet recruiting | Biological: IOV-5001 | Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Solid Tumors, Unresectable Solid Tumor | 106 | Mar 2034 | ≤ 2,781 d | 2026-08-06 |
| A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue SarcomaNCT07741877Objective Response RateOpen-label · Treatment | Phase 2 | Not yet recruiting | Biological: Lifileucel | Sarcoma, Soft Tissue Sarcoma (STS), Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Dedifferentiated Liposarcoma (DDLPS) | 80 | 2033-09-01 | in 2,570 d | 2026-08-03 |
| A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced MelanomaNCT07288203Objective Response RateOpen-label · Treatment | Phase 2 | Active, not recruiting | Biological: Lifileucel | Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma | 100 | Dec 2032 | ≤ 2,326 d | 2026-04-20 |
| A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive LifileucelNCT06940739Safety and TolerabilityOpen-label · Other | Phase 1/2 | Recruiting | Biological: IOV-3001 | Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma | 42 | Jun 2032 | ≤ 2,142 d | 2026-06-15 |
| Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung CancerNCT04614103Objective Response RateNon-randomized · Open-label · Treatment | Phase 2 | Recruiting | Biological: LN-145, LN-145 | Metastatic Non Small Cell Lung Cancer | 170 | Dec 2030 | ≤ 1,595 d | 2026-06-26 |
| A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.NCT06481592Objective Response RateOpen-label · Treatment | Phase 2 | Recruiting | Biological: Lifileucel | Endometrial Cancer | 60 | May 2028 | ≤ 651 d | 2025-10-30 |
| Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.NCT05727904Objective Response Rate and Progression Free SurvivalRandomized · Open-label · Treatment | Phase 3 | Recruiting | Biological: Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period | Metastatic Melanoma, Unresectable Melanoma, Melanoma | 670 | 2028-03-01 | in 560 d | 2026-06-26 |
| A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung CancerNCT05361174Phase I: Safety of IOV-4001Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Biological: IOV-4001 | Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | 53 | Sep 2027 | ≤ 407 d | 2026-06-11 |
| Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult ParticipantsNCT06566092Incidence rate of Treatment-Emergent Adverse EventsNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Biological: LN-145/LN-144 | Soft Tissue Sarcoma, Primary Central Nervous System Carcinoma, Melanoma, Rhabdomyosarcoma, Ewing Sarcoma | 40 | Jul 2026 | — | 2026-04-06 |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsNCT03645928Objective Response RateNon-randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: After reviewing the available safety and efficacy data to date, Iovance concluded that the study reached the required number of events for evaluation of study endpoints. | Biological: Lifileucel, LN-145, LN-145-S1 · Drug: Pembrolizumab, Ipilimumab, Nivolumab, Nivolumab-relatlimab, Cisplatin, Carboplatin, Paclitaxel, Nab paclitaxel, Pemetrexed | Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer | 225 | 2026-02-20actual | — | 2026-05-15 |
| Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical CarcinomaNCT03108495results2026-07-31Cohort 1 and 2: Objective Response RateNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: After reviewing available safety and efficacy data to date, Iovance concluded the study reached the required number of events for evaluation of study endpoints. | Biological: LN-145, LN-145 + pembrolizumab | Cervical Carcinoma | 210 | 2025-08-22actual | — | 2026-07-31 |
| Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLLNCT04155710Phase I: RP2D (Recommended Phase 2 Dose)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: IOV-2001 · Drug: Low dose IL-2, High dose IL-2, IL-2 | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 7 | 2024-11-11actual | — | 2025-12-24 |
| Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic MelanomaNCT02360579results2025-12-09Disease Assessment for Objective Response RateNon-randomized · Open-label · TreatmentStudy Protocol: Protocol V9.0 ↗ · Study Protocol: Protocol V8.0 ↗ · Study Protocol: Protocol V3.0 ↗ · Study Protocol: Protocol V4.0 ↗ · Study Protocol: Protocol V5.0 (Incorporating Amendments 1-4) ↗ · Study Protocol: Protocol V7.0_(Incorporating Amendments 1 through 6) ↗ · Study Protocol: Protocol V6.0 (Incorporating Amendments 1-5) ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Lifileucel | Metastatic Melanoma | 220 | 2024-10-24actual | — | 2026-03-25 |
| Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & NeckNCT03083873results2023-10-12Objective Response RateNon-randomized · Open-label · TreatmentStudy Protocol: Version 1 ↗ · Study Protocol: Version 2 ↗ · Study Protocol: Version 3 ↗ · Study Protocol: Version 4 ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: LN-145, LN-145-S1 | Squamous Cell Carcinoma of the Head and Neck | 64 | 2022-08-08actual | — | 2023-10-12 |
| Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung CancerNCT03419559Objective Response RateOpen-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: The treatment landscape for NSCLC has evolved in the past year. An additional NSCLC arm will be added to the IOV-COM-202 study using TIL + pembrolizumab. | Biological: LN-145 · Drug: Durvalumab | Non Small Cell Lung Cancer | 0 | Dec 2021 | — | 2019-04-16 |
| Expanded Access Program of AMTAGVI That is Out of Specification for Commercial ReleaseNCT05398640expanded access | — | Available | Biological: OOS AMTAGVI | Unresectable Melanoma, Metastatic Melanoma | — | — | — | 2026-04-20 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19